All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Bookmark this article
The AML Hub is pleased to present a visual abstract summarizing the preliminary safety and efficacy results from the phase I/II trial (NCT05086315) investigating SAR443579 (SAR’579), a trifunctional anti-CD123 NKp46×CD16 natural killer cell engager, in patients with relapsed/refractory acute myeloid leukemia.1,2
Preliminary results from this trial were presented by Stein1,2 at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) 2023 Hybrid Congress. No dose-limiting toxicities were identified. Based on the results of this analysis, the study protocol was amended to assess a higher dose of SAR’579.1,2
To download this visual abstract, click below.Download here
The latest developments on novel agents in the treatment of AML: Updates from #ASCO23 and EHA
Here, we summarize the latest updates on five novel agents: iadademstat, ZN-d5, azenosertib, ziftomenib, and olutasidenib for the treatment of AML were...
The latest updates on oral azacitidine in AML
We summarize several subgroup analyses from the phase III QUAZAR AML-001 trial presented at EHA 2023 and a phase I trial of oral azacitidine plus venetoclax presented at ASCO and EHA 2023.
Subscribe to get the best content related to AML delivered to your inbox